Antineoplastics
1
Reactions 1429 - 24 Nov 2012 S Antineoplastics Immune thrombocytopenia purpura in a child: case report A 12-year-old boy developed immune thrombocytopenic pupura (ITP) during chemotherapy for acute myeloid leukaemia (AML). The boy was diagnosed with AML in September 2009. Chemotherapy was started with pirarubicin and cytarabine [routes and dosages not stated]. He then received, in sequence, cytarabine 1 g/m 2 every 12 hours [route not stated] with mitoxantrone [route and dosage not stated], cytarabine 2 g/m 2 every 12 hours with etoposide [route and dosage not stated], cytarabine 3 g/m 2 every 12 hours, and cytarabine 2 g/m 2 every 12 hours with etoposide [durations not stated]. Chemotherapy was completed in May, and complete remission was achieved. Three months after completing chemotherapy, in September 2010, he developed pinpoint skin bleeding, petechiae ecchymosis, nasal bleeding and haematuria. Laboratory findings revealed a low platelet count, elevated platelet antibodies (68.11%), the presence of antiplatelet antibody-producing CD19+ B cell clones and obvious T cell activation. Following bone marrow analysis, ITP was diagnosed. Methylprednisolone was administered for 3 days. The boy’s platelet count initially increased, then began to decrease again from the fourth day. His platelet count remained low despite treatment with methylprednisolone, immune globulin and immunosuppressants. He underwent a peripheral blood stem cell transplant in January 2011. A haemogram was normal after 7 months. Guo L, et al. Immune thrombocytopenia following successful chemotherapy of acute leukemia: Report of 2 cases. Zhongguo Dang Dai Er Ke Za Zhi 14: 464-465, No. 6, 15 Jun 2012 [Chinese; summarised from a translation] - China 803079954 » Editorial comment: The authors describe a second patient who develops ITP during chemotherapy, but individual drugs were not identified. 1 Reactions 24 Nov 2012 No. 1429 0114-9954/10/1429-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
-
Upload
hoangtuong -
Category
Documents
-
view
212 -
download
0
Transcript of Antineoplastics
Reactions 1429 - 24 Nov 2012
SAntineoplastics
Immune thrombocytopenia purpura in a child:case report
A 12-year-old boy developed immune thrombocytopenicpupura (ITP) during chemotherapy for acute myeloidleukaemia (AML).
The boy was diagnosed with AML in September 2009.Chemotherapy was started with pirarubicin and cytarabine[routes and dosages not stated]. He then received, insequence, cytarabine 1 g/m2 every 12 hours [route notstated] with mitoxantrone [route and dosage not stated],cytarabine 2 g/m2 every 12 hours with etoposide [route anddosage not stated], cytarabine 3 g/m2 every 12 hours, andcytarabine 2 g/m2 every 12 hours with etoposide [durationsnot stated]. Chemotherapy was completed in May, andcomplete remission was achieved. Three months aftercompleting chemotherapy, in September 2010, hedeveloped pinpoint skin bleeding, petechiae ecchymosis,nasal bleeding and haematuria. Laboratory findingsrevealed a low platelet count, elevated platelet antibodies(68.11%), the presence of antiplatelet antibody-producingCD19+ B cell clones and obvious T cell activation.Following bone marrow analysis, ITP was diagnosed.
Methylprednisolone was administered for 3 days. Theboy’s platelet count initially increased, then began todecrease again from the fourth day. His platelet countremained low despite treatment with methylprednisolone,immune globulin and immunosuppressants. He underwenta peripheral blood stem cell transplant in January 2011. Ahaemogram was normal after 7 months.Guo L, et al. Immune thrombocytopenia following successful chemotherapy ofacute leukemia: Report of 2 cases. Zhongguo Dang Dai Er Ke Za Zhi 14: 464-465,No. 6, 15 Jun 2012 [Chinese; summarised from a translation] - China 803079954
» Editorial comment: The authors describe a secondpatient who develops ITP during chemotherapy, butindividual drugs were not identified.
1
Reactions 24 Nov 2012 No. 14290114-9954/10/1429-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
